---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-101618"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2025-08-04T23:59:59+00:00"
generated_at: "2026-05-17T21:32:23.146055+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology confirms HNSCC enrollment guidance for Phase 1 MICVO trial after ClinicalTrials.gov revision

## Summary
- Revised ClinicalTrials.gov entry for MICVO (PYX-201) Phase 1 monotherapy trial reflects maximum patient enrollment per protocol.
- Company reaffirms prior HNSCC patient enrollment estimates for Part 2 dose expansion as disclosed in May 15, 2025 10-Q.
- No change to trial design or guidance; revision is administrative and consistent with industry practice.

## SEC filing metadata
- accession: 0000950170-25-101618
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2025-08-04T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017025101618/0000950170-25-101618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017025101618/pyxs-20250804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-101618
- JSON: https://secwatch.observer/filing/0000950170-25-101618.json
- Plain text: https://secwatch.observer/filing/0000950170-25-101618.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.